Also known as atai Life Sciences, Beckley Psytech, and Atai Beckley N.V..
None yet. When a new project in the record names AtaiBeckley as owner, partner or investor, it shows here.
Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.
Adds clinical-stage neuroplastogens, including lead program BPL-003 for treatment‑resistant depression; transaction approved by AtaiBeckley shareholders.
Revenue rose 48% to $23.0bn driven by Mounjaro and Zepbound; updated 2026 revenue guidance to $85–87bn; retatrutide Phase 3 package complete supporting a Q1 2027 BLA.
